These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 9408450)
1. Epidemiology of toxic nephropathies. Elseviers MM; De Broe ME Adv Nephrol Necker Hosp; 1997; 27():241-62. PubMed ID: 9408450 [No Abstract] [Full Text] [Related]
2. 5-ASA therapy and renal function in inflammatory bowel disease. Siveke JT; Egert J; Sitter T; Schiemann U; Walcher P; Török HP; Glas J; Folwaczny C Am J Gastroenterol; 2005 Feb; 100(2):501. PubMed ID: 15667517 [No Abstract] [Full Text] [Related]
3. Safety of high doses of mesalazine during pregnancy. Marteau P; Seksik P; Couve S; Jian R Am J Gastroenterol; 2005 Aug; 100(8):1897-8. PubMed ID: 16086733 [No Abstract] [Full Text] [Related]
4. Which are the 5-ASA compound side effects and how is it possible to avoid them? Moum B Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S212-3. PubMed ID: 18816767 [No Abstract] [Full Text] [Related]
5. [Analgesics and kidney]. Aitio ML Duodecim; 1998; 114(9):841-8. PubMed ID: 11524803 [No Abstract] [Full Text] [Related]
6. Asymptomatic urinary anomalies, hematuria and proteinuria, in patients with inflammatory bowel disease. Preliminary study. Velciov S; Gluhovschi G; Sporea I; Trandafirescu V; Petrica L; Bozdog G; Gluhovschi C; Bob F; Gădălean F; Buzaş R; Bobu M; Voicu L Rom J Intern Med; 2011; 49(2):113-20. PubMed ID: 22303602 [TBL] [Abstract][Full Text] [Related]
8. [Drug-induced kidney diseases. I. Analgesics and non-steroidal antirheumatic drugs]. Hörl WH Med Monatsschr Pharm; 1986 Nov; 9(11):331-7. PubMed ID: 3807803 [No Abstract] [Full Text] [Related]
9. Methaemoglobinaemia and renal failure following mesalazine for treatment of inflammatory bowel disease. Druez A; Rahier JF; Hébuterne X J Crohns Colitis; 2014 Aug; 8(8):900-1. PubMed ID: 24486176 [No Abstract] [Full Text] [Related]
10. Mesalazine-associated acute tubulointerstitial nephritis in a patient with spondylarthropathy. Sari I; Birlik M; Cavdar C; Sarioglu S; Akpinar H; Onen F; Akkoc N N Z Med J; 2005 Sep; 118(1222):U1662. PubMed ID: 16222356 [No Abstract] [Full Text] [Related]
11. Analgesics and the kidney: recommendations of the National Kidney Foundation for the use of analgesics. Birbari AE J Med Liban; 1996; 44(3):144-5. PubMed ID: 9260403 [No Abstract] [Full Text] [Related]
12. Hypereosinophilia due to mesalazine treatment. Usta Y; Ozen H; Gurakan F; Uslu N; Saltik-Temizel IN; Demir H; Yuce A J Clin Gastroenterol; 2009 Apr; 43(4):382. PubMed ID: 19309777 [No Abstract] [Full Text] [Related]
13. 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link? De Broe ME; Stolear JC; Nouwen EJ; Elseviers MM Nephrol Dial Transplant; 1997 Sep; 12(9):1839-41. PubMed ID: 9306332 [No Abstract] [Full Text] [Related]
14. Mesalamine: safe at first look. Saubermann LJ; Wolf JL Inflamm Bowel Dis; 1999 May; 5(2):148-9. PubMed ID: 10338388 [No Abstract] [Full Text] [Related]
15. Mesalamine-induced pneumonitis during therapy for chronic inflammatory bowel disease: a pediatric case report. Kohli R; Melin-Aldana H; Sentongo TA J Pediatr Gastroenterol Nutr; 2005 Oct; 41(4):479-82. PubMed ID: 16205520 [No Abstract] [Full Text] [Related]
16. Massive pericardial effusion in a child following the administration of mesalamine. Kaiser GC; Milov DE; Erhart NA; Bailey DJ J Pediatr Gastroenterol Nutr; 1997 Oct; 25(4):435-8. PubMed ID: 9327378 [No Abstract] [Full Text] [Related]
17. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. Mulder CJ; van den Hazel SJ Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596 [TBL] [Abstract][Full Text] [Related]